Home
http://www.virbac.fr/ http://www.boehringer-ingelheim.com/ http://www.novartis.com/ http://www.animalhealth.bayerhealthcare.com/
vetcontact
Vetrinär
Tiermedizin
  WELCOME  
vetcontact
Vetrinär
Tiermedizin
  Home  
  Login / Newsletter  
vetcontact
Vetrinär
Tiermedizin
  CONTACTS  
vetcontact
Vetrinär
Tiermedizin
  Classifieds  
  New Products  
  VetCompanies  
  VetSchools  
vetcontact
Vetrinär
Tiermedizin
  PROFESSION  
vetcontact
Vetrinär
Tiermedizin
  Edutainment  
  VetAgenda  
  Presentations  
  Posters  
  ESAVS  
  Specialisation  
vetcontact
Vetrinär
Tiermedizin
  INSIGHT  
vetcontact
Vetrinär
Tiermedizin
  Congress News  
  Picture Galleries  
vetcontact
Vetrinär
Tiermedizin
  PRODUCTS  
vetcontact
Vetrinär
Tiermedizin
  Bayer  
  Boehringer Ing.  
  Novartis  
  Virbac

 
  Simply book for less...  
    

Bovine    Equine    Small Animal Practice    Swine Practice    Articles    Vetjournal    
deutsch english español polski francais
Home / WELCOME / Archiv / Small Animal Practice /     
 
Gemcitabine as radiosensitizer for nonresectable oral SCC in cats
Squamous cell carcinomas (SCC) in the oral cavity of cats are fairly common seen. When diagnosed, they are often in a nonresectable stage, and they tend to response very poor to chemotherapy. This small study on eight cats describes a very interesting and rather effective therapeutic alternative: a radiosensitizer plus radiotherapy!

Eight cats with locally advanced, oral squamous cell carcinoma (SCC) were treated with a combination of gemcitabine and palliative radiotherapy.

Low-dose gemcitabine was administered twice weekly (25 mg/m2) in conjunction with megavoltage radiation in 6 Gray (Gy) fractions for a total dose of 36 Gy.

Responses included two complete and four partial responses, and two cats had no response to therapy.

Median duration of remission was 42.5 days (range, 11 to 85 days).
Median survival time was 111.5 days (range, 11 to 234 days).

This data suggests that a combination of low-dose gemcitabine and palliative radiation therapy may be tolerable for cats with oral SCC and may cause a therapeutic benefit.



Source: Pamela D. Jones, Louis-Philippe de Lorimier, Barbara E. Kitchell, John M. Losonsky (2003): Gemcitabine as a Radiosensitizer for Nonresectable Feline Oral Squamous Cell Carcinoma. In: Journal of the American Animal Hospital Association 39:463-467 (2003)



Tell a friend   |   Print version   |   Send this article

SMALL ANIMAL PRACTICE

The expression of Vitamin D receptors in dogs
There is growing evidence linking low blood vitamin D concentration to numerous diseases in people and in dogs. Vitamin D influences cellular function by signaling through the vitamin D receptor (VDR). Little is known about which non-skeletal tissues express the VDR or how inflammation influences its expression in the dog.
The objectives of this recently online published study were to define which non-skeletal canine tissues express the VDR and to investigate expression in inflamed small intestine.

  • Complex atlanto-axial malformation in a rabbitmembers
  • Fluorescein sodium-guided resection of intracranial lesions in dogsmembers
  • Ultrasound and clinical findings in cats with urethral obstructionmembers
  • Novel technique to measure plasma lipids in diabetic dogsmembers
  • Prevalence and disease associations in feline thrombocytopeniamembers
  • Optic neuritis in dogs: an updatemembers
  • Brachycephalic airway syndrome - differences between pugs and French bulldogsmembers
  • Prognostic factors in cats with HCMmembers
  • Ureteral Papilla Implantation in Cats Undergoing Renal Transplantationmembers
  • Storage lesion in canine packed erythrocytesmembers
  • Drug-induced infiltrative lung disease with cytarabine and prednisonemembers
  • Laparoscopic-assisted Gastropexy and the Gastrointestinal Transit Time in Dogsmembers


  • [ Home ] [ About ] [ Contact / Request ][ Disclaimer ]

    Copyright © 2001-2016 VetContact GmbH
    All rights reserved